Abstract: A BRD9 protein degrading compound of structure or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.
Type:
Grant
Filed:
December 2, 2021
Date of Patent:
July 4, 2023
Assignee:
C4 Therapeutics, Inc.
Inventors:
Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
Abstract: Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative bacterial infections. Compounds selected for conversion to potential Gram-negative antibacterial compounds were identified based on compounds having low globularity and low flexibility. Amine substituents were then strategically added to the selected compounds to provide compounds having antibacterial activity against Gram-negative bacteria.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
July 4, 2023
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Paul J. Hergenrother, Emily Jane Geddes, Bryon Shane Drown, Stephen E. Motika, Erica Nicole Parker
Abstract: A solid form of RAD1901-2HCl having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 11.53 degrees 2?±0.2 degrees 2?, and compositions, methods, and processes thereof.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
May 9, 2023
Assignee:
Radius Pharmaceuticals, Inc.
Inventors:
Michael Paul Cruskie, Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Abstract: The present disclosure relates to pharmaceutical compositions of tranexamic acid and methods of using the compositions. The pharmaceutical compositions of the present disclosure are stable and suitable for topical application.
Abstract: The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
March 7, 2023
Assignee:
JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
Inventors:
Dongfang Shi, Jianghua Zhu, Jie Gu, Xi Cheng, Yan Yang, He Zhou, Pengfei Li, Fan Wu
Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.
Type:
Grant
Filed:
August 12, 2020
Date of Patent:
February 14, 2023
Assignee:
GILEAD SCIENCES, INC.
Inventors:
Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Jason K. Perry, Natalie Seeger, Kirk L. Stevens, Zhongdong Zhao
Abstract: A platinum(II) complex of formula (I), or a pharmaceutically acceptable solvate or tautomer thereof, wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; or wherein R1 and R2 together form a five-, six-, or seven-membered ring with the nitrogen atoms to which they are attached; and X is a nitrate anion, a hexafluorophosphate anion, a hexafluoroantimonate anion, a trifluoromethanesulfonate anion, a tetrafluoroborate anion, a perchlorate anion, or a halide anion. A pharmaceutical composition containing the platinum(II) complex of formula (I), and a method of treating cancer are also disclosed.
Type:
Grant
Filed:
February 1, 2021
Date of Patent:
February 7, 2023
Assignees:
KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS, KING SAUD UNIVERSITY
Inventors:
Adam Ahmed Abdullah Sulaiman, Abdul Rajjak Shaikh, Ali Alhoshani, Anvarhusein A. Isab
Abstract: The present invention discloses compounds according to Formula I: Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFN?, IL12 and/or IL23 by administering the compound of the invention.
Type:
Grant
Filed:
October 11, 2018
Date of Patent:
January 31, 2023
Assignee:
GALAPAGOS NV
Inventors:
Steven Emiel Van Der Plas, Oscar Mammoliti, Sébastien Laurent Xavier Martina, Pieter Isabelle Roger Claes, Ghjuvanni Petru Diunisu Coti, Denis Maurice Annoot, Miriam López Ramos, René Alexandre Galien, David Amantini, Reginald Christophe Xavier Brys
Abstract: The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by autotaxin.
Type:
Grant
Filed:
July 20, 2020
Date of Patent:
November 1, 2022
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Christian Andreas Kuttruff, Tom Bretschneider, Cédrickx Godbout, Hannes Fiepko Koolman, Domnic Martyres, Gerald Juergen Roth